WO2009020645A3 - Matriptase protein and uses thereof - Google Patents

Matriptase protein and uses thereof Download PDF

Info

Publication number
WO2009020645A3
WO2009020645A3 PCT/US2008/009512 US2008009512W WO2009020645A3 WO 2009020645 A3 WO2009020645 A3 WO 2009020645A3 US 2008009512 W US2008009512 W US 2008009512W WO 2009020645 A3 WO2009020645 A3 WO 2009020645A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
uterine
esophageal
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/009512
Other languages
French (fr)
Other versions
WO2009020645A2 (en
Inventor
Christian Rohlff
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Genome Sciences UK Ltd
ER Squibb and Sons LLC
Original Assignee
Oxford Genome Sciences UK Ltd
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Genome Sciences UK Ltd, Medarex LLC filed Critical Oxford Genome Sciences UK Ltd
Priority to DK08795130.7T priority Critical patent/DK2185933T3/en
Priority to EP08795130.7A priority patent/EP2185933B1/en
Priority to ES08795130.7T priority patent/ES2550754T3/en
Priority to AU2008284271A priority patent/AU2008284271B2/en
Priority to JP2010519988A priority patent/JP5864856B2/en
Publication of WO2009020645A2 publication Critical patent/WO2009020645A2/en
Publication of WO2009020645A3 publication Critical patent/WO2009020645A3/en
Priority to US12/701,566 priority patent/US8420091B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.
PCT/US2008/009512 2007-08-07 2008-08-07 Matriptase protein and uses thereof Ceased WO2009020645A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK08795130.7T DK2185933T3 (en) 2007-08-07 2008-08-07 MATRIPTASE PROTEIN AND APPLICATIONS THEREOF
EP08795130.7A EP2185933B1 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof
ES08795130.7T ES2550754T3 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof
AU2008284271A AU2008284271B2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof
JP2010519988A JP5864856B2 (en) 2007-08-07 2008-08-07 Matriptase protein and use thereof
US12/701,566 US8420091B2 (en) 2007-08-07 2010-02-07 Matriptase protein and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96383707P 2007-08-07 2007-08-07
US60/963,837 2007-08-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/701,566 Continuation US8420091B2 (en) 2007-08-07 2010-02-07 Matriptase protein and uses thereof

Publications (2)

Publication Number Publication Date
WO2009020645A2 WO2009020645A2 (en) 2009-02-12
WO2009020645A3 true WO2009020645A3 (en) 2009-05-07

Family

ID=40239716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009512 Ceased WO2009020645A2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Country Status (7)

Country Link
US (1) US8420091B2 (en)
EP (1) EP2185933B1 (en)
JP (2) JP5864856B2 (en)
AU (1) AU2008284271B2 (en)
DK (1) DK2185933T3 (en)
ES (1) ES2550754T3 (en)
WO (1) WO2009020645A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20120294800A1 (en) * 2009-01-07 2012-11-22 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CN102341412B (en) * 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 Fully human antibody specific to CADM1
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers SPECIFIC ADMINISTRATION OF TOXINS CONJUGATED TO ANTIBODIES UNTIL ACTIVATED MATRIPTASE
KR20160079818A (en) * 2013-11-25 2016-07-06 옥스포드 바이오테라퓨틱스 리미티드 Antibodies anti matriptase for the treatment of cancer
KR102441107B1 (en) * 2014-11-07 2022-09-13 후지쿠라 가세이 가부시키가이샤 Method for detecting arteriosclerosis and cancer using deoxyhyfucin/synthase gene as an index
CA3017958C (en) 2016-03-18 2024-03-12 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023524A2 (en) * 1999-09-30 2001-04-05 The Regents Of The University Of California Membrane type serine protease 1 (mt-sp1) and uses thereof
WO2001029056A1 (en) * 1999-10-20 2001-04-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in carcinomas
US6649741B1 (en) * 1998-02-20 2003-11-18 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in carcinomas
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (en) 1999-03-12 2007-09-19 Univ Georgetown MATRIPTASE, SERINE PROTEASE, AND USE THEREOF
US6447978B1 (en) 1999-12-03 2002-09-10 Kodak Polychrome Graphics Llc Imaging member containing heat switchable polymer and method of use
EP1252300B1 (en) 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6903201B2 (en) 2001-01-05 2005-06-07 Curagen Corporation Proteins and nucleic acids encoding same
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
CN1985489B (en) 2004-07-09 2012-05-09 艾利森电话股份有限公司 Method and arrangement for providing different services in multimedia communication system
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649741B1 (en) * 1998-02-20 2003-11-18 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in carcinomas
WO2001023524A2 (en) * 1999-09-30 2001-04-05 The Regents Of The University Of California Membrane type serine protease 1 (mt-sp1) and uses thereof
WO2001029056A1 (en) * 1999-10-20 2001-04-26 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in carcinomas
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHO E G ET AL: "N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 30 NOV 2001, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 44581 - 44589, XP008100687, ISSN: 0021-9258 *
EVERTS MAAIKE: "Targeted therapies directed to tumor-associated antigens", DRUGS OF THE FUTURE, vol. 30, no. 10, October 2005 (2005-10-01), pages 1067 - 1076, XP008103658, ISSN: 0377-8282 *
OBERST MICHAEL D ET AL: "The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 29, 18 July 2003 (2003-07-18), pages 26773 - 26779, XP008100685, ISSN: 0021-9258 *
PEDLEY R B: "Pharmacokinetics of monoclonal antibodies. Implications for their use in cancer therapy", CLINICAL IMMUNOTHERAPEUTICS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 6, no. 1, 1 January 1996 (1996-01-01), pages 54 - 67, XP009100791, ISSN: 1172-7039 *
TAKEUCHI T ET AL: "CELLULAR LOCALIZATION OF MEMBRANE-TYPE SERINE PROTEASE 1 AND IDENTIFICATION OF PROTEASE-ACTIVATED RECEPTOR-2 AND SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR AS SUBSTRATES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26333 - 26342, XP001000977, ISSN: 0021-9258 *
TSUZUKI SATOSHI ET AL: "Evidence for the occurrence of membrane-type serine protease 1/matriptase on the basolateral sides of enterocytes", BIOCHEMICAL JOURNAL, vol. 388, no. Part 2, June 2005 (2005-06-01), pages 679 - 687, XP008103674, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
JP5864856B2 (en) 2016-02-17
EP2185933A2 (en) 2010-05-19
EP2185933B1 (en) 2015-10-07
ES2550754T3 (en) 2015-11-12
WO2009020645A2 (en) 2009-02-12
JP2010535506A (en) 2010-11-25
JP2014223083A (en) 2014-12-04
DK2185933T3 (en) 2015-10-26
AU2008284271B2 (en) 2014-03-13
US20100285017A1 (en) 2010-11-11
US8420091B2 (en) 2013-04-16
AU2008284271A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
WO2007141280A3 (en) Proteins
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009020645A3 (en) Matriptase protein and uses thereof
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2009087462A3 (en) Ephrin type-a receptor 10 protein
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
ZA200803517B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200803430B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200804509B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2003087831A3 (en) Proteins involved in breast cancer
ZA200803516B (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
HK1214611A1 (en) Ly75 as cancer therapeutic and diagnostic target
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
WO2010054397A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2007101063A3 (en) Treatment of development-related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795130

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008284271

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010519988

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008284271

Country of ref document: AU

Date of ref document: 20080807

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008795130

Country of ref document: EP